Comparison of the Incidence of Episiotomy Site Infection With and Without Use of Prophylactic Antibiotics

Comparison of the Incidence of Episiotomy Site Infection in the two groups Who Use Prophylactic Antibiotics and dont Use it after Vaginal Delivery in Primigravid Patients Who Referring to bentolhoda hospital in bojnourd

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190129042545N1

Enrollment

140

Registered

2019-02-23

Start date

2019-02-03

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

episiotomy site infection. Vulvovaginal ulceration and inflammation in other diseases classified elsewhere

Interventions

Intervention 1: Intervention group: capsul cephalexin 500 mg that is an antibiotic, should be used each 6 hour for 7 days. Intervention 2: Control group: plasebo with similar shape to cephalexin, shou

Eligibility

Sex/Gender

Female

Age

16 Years to 35 Years

Inclusion criteria

Inclusion criteria: 16 to 35 years old mediolateral episiotomy mother without underlying disease no history of chemo therapy no allergy to antibiotics not using immunosuppressive or antibiotic medicine not using alcohol or tobacco absence of symptomatic vaginitis or lesion or skin allergy in preinea

Exclusion criteria

Exclusion criteria: Prolonged rupture of membrane (more than 18 hour). Vaginal delivery with tools. Third- and fourth-degree perineal tearing

Design outcomes

Primary

Measure	Time frame
Percent of Episiotomy site infection with usage of prophilactic antibiotics. Timepoint: 7 days after vaginal delivery. Method of measurement: obzervation of episiotomy site by examiner.;Percent of Episiotomy site infection without usage of prophilactic antibiotics. Timepoint: 7 days after vaginal delivery. Method of measurement: obzervation of episiotomy site by examiner.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtieh Kalateh

Bojnourd University of Medical Sciences

ateeh.kalateh@yahoo.com+98 58 3223 6551

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026